DK1874341T3 - Erythrocytter, der indeholder arginin deiminase - Google Patents

Erythrocytter, der indeholder arginin deiminase

Info

Publication number
DK1874341T3
DK1874341T3 DK06744562T DK06744562T DK1874341T3 DK 1874341 T3 DK1874341 T3 DK 1874341T3 DK 06744562 T DK06744562 T DK 06744562T DK 06744562 T DK06744562 T DK 06744562T DK 1874341 T3 DK1874341 T3 DK 1874341T3
Authority
DK
Denmark
Prior art keywords
arginine deiminase
containing arginine
erythrocytes containing
erythrocytes
deiminase
Prior art date
Application number
DK06744562T
Other languages
English (en)
Inventor
Yann Godfrin
Pierre-Olivier Goineau
Original Assignee
Erytech Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erytech Pharma filed Critical Erytech Pharma
Application granted granted Critical
Publication of DK1874341T3 publication Critical patent/DK1874341T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006—Arginine deiminase (3.5.3.6)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK06744562T 2005-04-25 2006-04-25 Erythrocytter, der indeholder arginin deiminase DK1874341T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0504122A FR2884717B1 (fr) 2005-04-25 2005-04-25 Erythrocytes renfermant de l'arginine deiminase
PCT/IB2006/001004 WO2006114691A1 (en) 2005-04-25 2006-04-25 Erythrocytes containing arginine deiminase

Publications (1)

Publication Number Publication Date
DK1874341T3 true DK1874341T3 (da) 2009-08-03

Family

ID=35787979

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06744562T DK1874341T3 (da) 2005-04-25 2006-04-25 Erythrocytter, der indeholder arginin deiminase

Country Status (17)

Country Link
US (2) US9125876B2 (da)
EP (1) EP1874341B1 (da)
JP (1) JP5339899B2 (da)
KR (1) KR101431650B1 (da)
CN (1) CN101163497B (da)
AT (1) ATE432711T1 (da)
AU (1) AU2006238917C1 (da)
CA (1) CA2606420C (da)
CY (1) CY1109353T1 (da)
DE (1) DE602006007122D1 (da)
DK (1) DK1874341T3 (da)
ES (1) ES2326549T3 (da)
FR (1) FR2884717B1 (da)
PL (1) PL1874341T3 (da)
PT (1) PT1874341E (da)
SI (1) SI1874341T1 (da)
WO (1) WO2006114691A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
US20100316620A1 (en) * 2008-02-13 2010-12-16 Vanessa Bourgeaux Formulation and Method for the Prevention and Treatment of Skeletal Manifestation of Gaucher's Disease
US8815232B2 (en) 2008-08-26 2014-08-26 Kyon Biotech Ag Compositions and methods for treating cancer
FR2940087B1 (fr) 2008-12-18 2011-05-06 Lab Francais Du Fractionnement Erythrocytes contenant du facteur viii, preparation et utilisations.
WO2012021512A2 (en) 2010-08-10 2012-02-16 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9033948B2 (en) * 2011-04-19 2015-05-19 Fenwel, Inc. Single collection bag blood collection system, method and apparatus
FR3005420B1 (fr) 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
AU2014348683B2 (en) 2013-11-18 2020-11-05 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
FR3017299B1 (fr) * 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
KR102717969B1 (ko) 2014-02-21 2024-10-15 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) 글리코타겟팅 치료제
ES2865825T3 (es) 2014-04-01 2021-10-18 Rubius Therapeutics Inc Procedimientos y composiciones para inmunomodulación
EP3344575B1 (en) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
AU2017207736A1 (en) 2016-01-11 2018-07-12 Rubius Therapeutics, Inc. Compositions and methods related to multimodal therapeutic cell systems for immune indications
JP7602702B2 (ja) 2016-05-03 2024-12-19 ステムセル テクノロジーズ カナダ インコーポレーテッド 寛容性を誘導するための生体分子の細胞内送達
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
EP3449935A1 (en) * 2017-08-31 2019-03-06 Erytech Pharma Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
WO2019042628A1 (en) 2017-08-31 2019-03-07 Erytech Pharma ARGININE DEIMINASE ENCAPSULATED WITHIN ERYTHROCYTES AND THEIR USE IN THE TREATMENT OF CANCER AND ARGINASE-1 DEFICIENCY
WO2020009740A2 (en) * 2018-04-25 2020-01-09 Washington University Compositions and methods of use thereof for treatment of metabolic diseases and related disorders
EA202092723A1 (ru) 2018-05-09 2021-04-09 Зе Юниверсити Оф Чикаго Композиции и способы, касающиеся иммунной толерантности
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
EP4149440A1 (en) 2020-05-11 2023-03-22 Erytech Pharma Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof
CN113750232B (zh) * 2021-09-12 2023-06-02 重庆医科大学 一种巨噬细胞膜包覆精氨酸脱亚胺酶/过氧化氢酶/ir780纳米粒、制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1051382A (da) * 1900-01-01
DE2740053A1 (de) * 1977-09-06 1979-05-03 Klaus Prof Dr Med Gersonde Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten
JPH0235081A (ja) 1988-07-26 1990-02-05 Agency Of Ind Science & Technol アルギニン・デイミナーゼおよびその用途
JPH0253490A (ja) 1988-08-16 1990-02-22 Agency Of Ind Science & Technol アルギニン・デイミナーゼ遺伝子
EP0361150B1 (de) * 1988-09-30 1994-12-14 Siemens Aktiengesellschaft Verfahren zum synchronisierten Umtasten eines Polarisationszustandes eines optischen Sendesignals eines optischen Übertragungssystems mit Überlagerungsempfang und Vorrichtung zur Durchführung des Verfahrens
JP2900279B2 (ja) 1989-08-02 1999-06-02 株式会社ジャパンエナジー 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤
FR2678512B1 (fr) * 1991-07-03 1995-06-30 Novacell Machine a internaliser.
JP3004788B2 (ja) 1991-10-28 2000-01-31 株式会社ジャパンエナジー アルギニンデイミナーゼ発現ベクター、形質転換微生物およびアルギニンデイミナーゼの製造法
US5372942A (en) * 1992-02-10 1994-12-13 Coriell Institute For Medical Research Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent
ATE272311T1 (de) * 1993-03-23 2004-08-15 Cbr Lab Inc Verfahren und vorrichtung zur einkapselung biologisch aktiver substanzen in zellen
US5804183A (en) * 1997-01-31 1998-09-08 Enzon, Inc. Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
US6482585B2 (en) * 1997-04-16 2002-11-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Storage and maintenance of blood products including red blood cells and platelets
US6183738B1 (en) * 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
KR100406268B1 (ko) 1999-12-24 2003-11-19 주식회사 안지오랩 아르기닌 디이미네이즈를 유효성분으로 하는 혈관신생에 의한 질환 치료용 조성물
WO2002009741A1 (en) * 2000-07-27 2002-02-07 Angiolab, Inc. The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis
WO2002044360A2 (en) * 2000-11-28 2002-06-06 Phoenix Pharmacologics, Inc. Modified arginine deiminase
AU2003282883B2 (en) * 2002-11-18 2008-12-04 Polaris Group Methods for inhibiting viral replication in vivo
WO2005026319A2 (en) * 2003-08-06 2005-03-24 The Regents Of Teh University Of California Erythrocytic cells and method for loading solutes

Also Published As

Publication number Publication date
HK1112187A1 (en) 2008-08-29
FR2884717A1 (fr) 2006-10-27
KR20080000678A (ko) 2008-01-02
KR101431650B1 (ko) 2014-08-20
CA2606420A1 (en) 2006-11-02
US9968663B2 (en) 2018-05-15
AU2006238917C1 (en) 2011-08-04
PT1874341E (pt) 2009-07-21
EP1874341A1 (en) 2008-01-09
FR2884717B1 (fr) 2009-07-03
JP2008538761A (ja) 2008-11-06
DE602006007122D1 (de) 2009-07-16
CY1109353T1 (el) 2014-07-02
US9125876B2 (en) 2015-09-08
US20080274092A1 (en) 2008-11-06
AU2006238917B2 (en) 2011-04-07
ATE432711T1 (de) 2009-06-15
WO2006114691A1 (en) 2006-11-02
US20160030532A1 (en) 2016-02-04
PL1874341T3 (pl) 2009-12-31
ES2326549T3 (es) 2009-10-14
CN101163497A (zh) 2008-04-16
AU2006238917A1 (en) 2006-11-02
SI1874341T1 (sl) 2009-08-31
EP1874341B1 (en) 2009-06-03
CN101163497B (zh) 2012-12-19
JP5339899B2 (ja) 2013-11-13
CA2606420C (en) 2015-01-27

Similar Documents

Publication Publication Date Title
DK1874341T3 (da) Erythrocytter, der indeholder arginin deiminase
DE602005027820D1 (de) Mehrfachpromotor-expressionskassetten zurgleichzeitigen zuführung von rnai-agentien
MX2008000294A (es) Activadores de dicicloalquil urea glucocinasa.
EA200800160A1 (ru) Композиты восстановленной ионной жидкостью целлюлозы в качестве матриц твёрдых подложек
MX2009004320A (es) Inhibidores de serina proteasa tipo tripsina, y su preparacion y uso.
AR059027A1 (es) Administracion de inhibidores de dipeptidil peptidasa
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
MX2010001589A (es) Nucleo absorbente.
MX376225B (es) Proteínas biológicas condicionalmente activas
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
MX2010005983A (es) Nucleo absorbente.
NO20081013L (no) 7-substituerte aza-indazoler, sammensetninger inneholdende disse, produksjonsmetode og anvendelse derav
EA200701771A1 (ru) Низкомолекулярные ингибиторы mdm2 и их применение
EA200900375A1 (ru) Твердые лимонно-кислые и винно-кислые соли ингибиторов dpp-iv
EA201100452A1 (ru) Лечение воспалительных состояний
ECSP099476A (es) Compuestos carboxamida y su uso como inhibidores de calpaína
UY29826A1 (es) Derivados de pirimidina, sales farmaceuticamente aceptables, esteres de los mismos hidrolisables in vivo, procesos de preparacion y aplicaciones
MY153198A (en) Inhibitors of protein aggregation
EA200700717A1 (ru) Сульфонамиды
NO20075111L (no) Farmasoytisk sammensetning
WO2008054534A3 (en) Screening systems utilizing rtp801
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
CY1116840T1 (el) Χρηση 24-norudca
PA8651301A1 (es) Nuevas piridinureas de antranilamida como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf)
MY150745A (en) Isoserine derivatives for use as coagulation factor ixa inhibitors